Kazia Therapeutics Limited (KZIA) gained 26.44% to close Tuesday's trading at $5.69. The stock has gained as much as 68% in the last 5 trading days. The lead program of Kazia, formerly known as Novogen, is GDC-0084, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer.
from RTT - Biotech http://ift.tt/2BF6gE0
via IFTTT
No comments:
Post a Comment